Who is sponsoring NCT05303142?

NCT05303142 is sponsored by University of Portsmouth.

What drugs are being tested in NCT05303142?

Interventions in NCT05303142: Heat Tolerance Assessment.

What condition does NCT05303142 study?

NCT05303142 studies Exertional Heat Illness.

Is NCT05303142 still recruiting?

NCT05303142 is currently completed. Last updated 22 May 2023.

Last reviewed 2023-05-22 · How we verify

NCT05303142

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparing Exertional Heat Illness Risk Factors Between Patients and Controls

Completed Last updated 22 May 2023

What this trial tests

trial testing Heat Tolerance Assessment in Exertional Heat Illness in 95 participants. Completed in 6 March 2023.

Timeline

1 February 2022

Primary endpoint
6 March 2023

6 March 2023

Quick facts

Lead sponsor	University of Portsmouth
Status	Completed
Study type	OBSERVATIONAL
Enrollment	95
Start date	1 February 2022
Primary completion	6 March 2023
Estimated completion	6 March 2023
Sites	1 location across United Kingdom

Drugs / interventions tested

Heat Tolerance Assessment

Conditions studied

Exertional Heat Illness — all drugs for Exertional Heat Illness →

Sponsor

University of Portsmouth

Who can join

Adults 18 to 40, any sex, with Exertional Heat Illness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The arduous nature of military training and operations require personnel to encounter high heat load, e.g., during intense physical exertion, particularly in the heat. These conditions reduce operational effectiveness and expose personnel to a risk of incapacitation and death from exertional heat illness (EHI). The primary aim of this study is to compare putative 'chronic' EHI risk factors between a cohort who have suffered a history of EHI and a control cohort with no EHI history. The secondary aim is to examine the influence of these EHI risk factors on thermoregulation during a standard heat tolerance assessment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Faecal microbiome, gastrointestinal integrity, inflammation and thermoregulation in recent exertional heat illness patients and matched controls.
Gould AAM, Walsh NP, Tipton MJ, Tipton MJ, et al · · 2026 · cited 3× · PMID 40551374 · DOI 10.1113/ep092849

Verify or expand the search:

Other University of Portsmouth trials

Trials by the same sponsor.

NCT06171594 — The Effect of Chlorhexidine on the Oral Microbiome and Saliva in Dental Erosion · NA · unknown
NCT06156618 — The Effect of Nitrate Supplement on the Oral Microbiome and Saliva in Dental Erosion · NA · unknown
NCT05618197 — Chronic Passive Heating in Healthy Older Adults · NA · completed
NCT05622747 — Acute Passive Heating in Healthy Older Adults · NA · completed
NCT05896488 — Sweat Response, Sweat Composition and Thermoregulatory Response to Exercise in Heat in Adults With Cystic Fibrosis on Mo · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05303142 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Portsmouth
Last refreshed: 22 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05303142.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing